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Calsequestrin is a high capacity Ca21-binding protein
in the junctional sarcoplasmic reticulum that forms a
quaternary complex with junctin, triadin, and the ryan-
odine receptor. Transgenic mice with cardiac-targeted
calsequestrin overexpression show marked suppression
of Ca21-induced Ca21 release, myocyte hypertrophy, and
premature death by 16 weeks of age (Jones, L. R., Su-
zuki, Y. J., Wang, W., Kobayashi, Y. M., Ramesh, V., Fran-
zini-Armstrong, C., Cleemann, L., and Morad, M. (1998)
J. Clin. Invest. 101, 1385–1393). To investigate whether
alterations in intracellular Ca21 trigger changes in the
b-adrenergic receptor pathway, we studied calseques-
trin overexpressing transgenic mice at 7 and 14 weeks of
age. As assessed by echocardiography, calsequestrin
mice at 7 weeks showed mild left ventricular enlarge-
ment, mild decreased fractional shortening with in-
creased wall thickness. By 14 weeks, the phenotype pro-
gressed to marked left ventricular enlargement and
severely depressed systolic function. Cardiac catheteri-
zation in calsequestrin mice revealed markedly im-
paired b-adrenergic receptor responsiveness in both 7-
and 14- week mice. Biochemical analysis in 7- and 14-
week mice showed a significant decrease in total b-ad-
renergic receptor density, adenylyl cyclase activity, and
the percent high affinity agonist binding, which was
associated with increased b-adrenergic receptor kinase
1 levels. Taken together, these data indicate that alter-
ations in b-adrenergic receptor signaling precede the
development of overt heart failure in this mouse model
of progressive cardiomyopathy.
Cardiac hypertrophy represents one of the most important
adaptive responses to increase mechanical load on the heart. In
an attempt to normalize excessive forces and work performed
per contractile unit, myocardial hypertrophy unloads the heart
by adding new sarcomeres in order to distribute tension across
a greater cellular mass (1). Although the induction of cardiac
hypertrophy can be viewed as a corrective response to elevated
stress, it is now clear that sustained hypertrophy initiates a
myopathic process leading to decompensated heart failure (2).
The molecular mechanisms that are responsible for this tran-
sition from a compensatory state to one of progressive chamber
enlargement and myocardial failure are poorly understood.
Derangement in a number of cellular processes have been
implicated in this pathological transition including abnormal-
ities in b-adrenergic receptor (bAR)1 signaling (3), activation of
mitogen-activated protein kinase pathways (4), and diminished
excitation-contraction coupling due to an altered spatial rela-
tionship between the L-type Ca21 channel and the ryanodine
receptor (5).
Chronic human heart failure is characterized by marked
abnormalities in bAR signaling that result from a number of
alterations including a 50% reduction in b1ARs without change
in b2AR density (6), increased levels of the inhibitory G protein
(6), and an increase in myocardial bARK1 activity (7). It re-
mains controversial whether alterations in the bAR system are
important in the pathogenesis of the failing heart. In this
regard, we have recently reported the striking finding that
cardiac overexpression of a bARK inhibitor prevents the devel-
opment of cardiomyopathy in a genetic model of murine heart
failure (8). Thus, abnormal bAR/G protein-coupling early in the
development of the failing heart appears to be a critical event
in the progressive nature of this disease (8).
Calsequestrin (CSQ) is a 55-kDa high capacity Ca12-binding
protein located in the lumen of the junctional sarcoplasmic
reticulum that forms a quaternary complex with junctin, tria-
din, and the ryanodine receptor, which are all required for the
normal regulation of Ca21 release by the ryanodine receptor
(9). Recently, we and others have characterized the electro-
physiological properties of transgenic mice with impaired Ca21
release achieved through cardiac overexpression of CSQ (10,
11). CSQ-overexpressing transgenic mice showed markedly re-
duced Ca21-induced Ca21 release (10, 11) and frequency of
Ca21 sparks (10). Interestingly, CSQ overexpression was asso-
ciated with myocyte hypertrophy, depressed cellular contrac-
tility, and induction of a fetal gene program. The purpose of
this study was to determine whether defects in bAR signaling
are associated with this mouse model of cellular contractile
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involved in the initiation of pathological hypertrophy and heart
failure.
MATERIALS AND METHODS
Experimental Animals—Transgenic mice overexpressing (CSQ) mice
were generated as described previously (10). Briefly, full-length canine
cardiac CSQ cDNA was fused to the a-myosin heavy chain promoter to
drive cardiac-targeted expression. Age-matched transgenic and wild-
type littermates of either sex were used. The genotype was determined
by polymerase chain reaction as described previously (10). The animals
in this study were handled according to approved protocols and the
animal welfare regulations of the University of North Carolina at
Chapel Hill and the Indiana University.
Transthoracic Echocardiography—Echocardiography was performed
in anesthetized mice (Avertin 2.5%, 14 ml/g intraperitoneally) using an
ATL HDI 5000 echocardiograph (ATL Ultrasound, Bothell, WA) as
described previously (8). Wild-type and CSQ mice at the age of 7 and 14
weeks were evaluated by noninvasive echocardiography followed by
invasive hemodynamics. In a separate group of mice, serial echocardio-
grams were obtained in the same animals over a 5-week period of time
with the initial study at 8.4 6 0.4 weeks of age and a second study
performed at 13.3 6 0.4 weeks of age.
The operator who performed and measured the echocardiograms was
blinded to the genotype of the animals. The following parameters were
measured: LVEDD; LVESD; % FS, calculated as (LVEDD 2 LVESD)/
LVEDD 3 100; SEPth; PWth, mVcfc, calculated as fractional shorten-
ing divided by ejection time multiplied by the square root of the R-R
interval. Estimated echocardiographic LV mass (in mg) was calculated
as ((LVEDD 1 SEPth 1 PWth)3 2 LVEDD3) 3 1.055, where 1.055
(mg/mm3) is the density of myocardium. Intraobserver and interob-
server variation for M-mode measurements was ,6% for internal di-
mensions and ,25% for wall thickness.
Cardiac Catheterization—Following echocardiography, hemody-
namic evaluation was performed in closed-chest mice as described pre-
viously (8, 12). Mice were anesthetized with a mixture of ketamine (100
mg/kg) and xylazine (2.5 mg/kg) and connected to a rodent ventilator
after endotracheal intubation. A 1.4 French high fidelity micromanom-
eter catheter (Millar Instruments) was inserted into the right carotid
and advanced retrograde into the LV. Hemodynamic measurements
were recorded on an 8-channel chart recorder and in digitized form at
2,000 Hz at base line and 45–60 s after injection of incremental doses of
isoproterenol (8). Experiments were then terminated, hearts were rap-
idly excised, and individual chambers were separated, weighed, and
frozen in liquid N2 for later biochemical analysis. Parameters measured
were heart rate, LV systolic pressure, LV end diastolic pressure, LV
dP/dtmax, and LV dP/dtmin. Ten sequential beats were averaged for
each measurement.
In separate CSQ overexpressing animals at 14 weeks of age, heart
rate was matched to the wild-type mice by right atrial pacing. Following
anesthesia and instrumentation as above, a bipolar pacing lead made
from a pair of fine filament-coated wires was introduced into the right
jugular vein and advanced into the right atrium. After a brief period of
stabilization, atrial pacing was initiated at a rate of 400/min, and
hemodynamic parameters were recorded as described.
Adenylyl Cyclase Activity, bAR Density, and Radioligand Binding—
Myocardial sarcolemmal membranes were prepared by homogenizing
whole hearts from 7- and 14-week-old mice in ice-cold buffer as de-
scribed previously (8, 12–14). Total bAR density was determined by
incubating 25 mg of cardiac sarcolemmal membranes with a saturating
concentration (80 pM) of [125I]cyanopindolol and 20 mM alprenolol to
define nonspecific binding (14). Typical nonspecific binding is '40% of
the total. Competition binding isotherms in sarcolemmal membranes
were done in triplicate with 18 varying concentrations of isoproterenol
(10213 M to 1024 M). Assays were conducted at 37 °C for 60 min and then
filtered over GF/C glass fiber filters (Whatman) that were washed and
counted in a g counter. Competition isotherms were analyzed by non-
linear least square curve fit (GraphPad Prism).
Adenylyl cyclase activity was performed on myocardial sarcolemmal
membranes from 7- and 14-week-old mice (8, 12, 14). Membranes (30 to
40 mg of protein) were incubated for 15 min at 37 °C with [a-32P]ATP
under basal conditions or indicated agonists, and cAMP was quantified
(8, 12, 14).
G Protein-coupled Receptor Kinase (GRK) Activity by Rhodopsin
Phosphorylation—GRK activity was measured in myocardial extracts
using rhodopsin-enriched rod outer segment membranes as an in vitro
substrate as described previously (12–14). Concentrated (Centricon,
Amicon, Inc.) cytosolic extract (300 mg of protein) was incubated with
rhodopsin-enriched rod outer segments in 50 ml of reaction buffer (20
mmol/liter Tris-Cl (pH 8.0), 2 mmol/liter EDTA, 10 mmol/liter MgCl2,
1mmol/liter dithiothreitol), and 0.1 mmol/liter ATP containing
[g-32P]ATP. The reactions were incubated in white light for 20 min and
quenched with 300 ml of ice-cold lysis buffer and then centrifuged for 15
min at 13,000 3 g. Sedimented proteins were resuspended in 20 ml of
protein gel loading dye and electrophoresed through SDS, 12% poly-
acrylamide gels. Phosphorylated rhodopsin was visualized by auto-
radiography and quantified using a PhoshorImager (Molecular
Dynamics).
Immunoblotting—Immunodetection of myocardial levels of bARK1
was performed on cytosolic extracts following immunoprecipitation us-
ing a monoclonal bARK1/2 antibody as described previously (8, 12, 14).
The ;80-kilodalton bARK1 protein was visualized with the monoclonal
antibody raised against an epitope within the carboxyl terminus of
bARK1 and chemiluminescent detection of anti-mouse IgG conjugated
with horseradish peroxidase (ECL, Amersham Pharmacia Biotech).
Northern Blot Analysis—Northern blotting was performed on LV
tissue obtained from 7- and 14-week CSQ and age-matched wild-type
mice as described previously (15). Total RNA was isolated by a modifi-
cation of the acid guanidine thiocyanate technique (RNeasy; Qiagen,
Valencia, CA). RNA (4 mg) was size-fractionated by denaturing gel
electrophoresis, transferred to nylon membranes by capillary action,
and cross-linked with UV light. Filters were prehybridized at 68 °C for
1 h and then hybridized for 4 h at 68 °C after the addition of 32P cDNA
probes labeled using random priming. Post hybridization filters were
washed under stringent conditions, and transcripts were detected by
autoradiography.
Statistical Analysis—Data are expressed as mean 6 S.E. To test for
statistical differences in serial echocardiographic data and hemody-
namic data between CSQ and wild-type mice, a two way repeated
measures analysis of variance was performed. When appropriate, post
hoc analysis with regard to differences in mean values between the
groups was conducted with a Newman-Keuls test. Statistical signifi-
cance between wild-type and CSQ mice at either 7 or 14 weeks of age for
the biochemical data, chamber weights, and echocardiographic vari-
ables was performed using Student’s t test.
RESULTS
CSQ Overexpression Results in a Cardiac Phenotype of Pro-
gressive Chamber Dilatation and Cardiac Failure—Transtho-
racic echocardiography was used to assess LV chamber size
and global cardiac function in transgenic and wild-type mice.
As shown in Fig. 1, overexpression of CSQ resulted in an early
phenotype of preserved chamber size and increased wall thick-
ness that progressed to one of LV enlargement and severe
cardiac dysfunction (Fig. 1). By 16 weeks of age all mice had
died. Summary echocardiographic data obtained in 7- and 14-
week-old mice are shown in Table I. At 7 weeks, CSQ mice
showed mild chamber enlargement, mild reduction in % FS,
and increased wall thickness. In contrast, at 14 weeks, severe
cardiac enlargement and marked cardiac dysfunction was evi-
dent with a reduction in wall thickness back to normal values.
In a separate group of age-matched CSQ and wild-type mice,
serial echocardiography was performed. Individual data points
FIG. 1. Representative M-mode echocardiographic tracings in
a wild-type and CSQ mouse. Transthoracic M-mode echocardio-
graphic tracings in a wild type, a 7-week-old CSQ mouse (CSQ 7 Wks),
and a 14-week-old CSQ mouse (CSQ 14 Wks). The double-sided arrows
indicate left ventricular internal dimensions. The CSQ mouse at 7
weeks of age has normal dimensions with increased septal (arrow-
heads) and posterior wall thickness. In contrast, the CSQ mouse at 14
weeks of age shows severe chamber enlargement, reduced cardiac per-
formance, and the lack of increased wall thickness. EDD, end-diastolic
dimension; ESD, end-systolic dimension.
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for 3 echocardiographic parameters are plotted for 12 CSQ mice
studied at 8.4 6 0.4 weeks of age and at a follow-up echocar-
diographic study 5 weeks later (Fig. 2). On the initial study, 7
of the 12 CSQ mice had normal LV chamber size and systolic
function as indicated by the normal LVEDD (Fig. 2A) and % FS
(Fig. 2B). This early phenotype was associated with a signifi-
cant increase in septal (Fig. 2C) and posterior wall thickness
(CSQ; 0.97 6 0.04 versus wild type; 0.74 6 0.03, mm, p ,
0.001). In contrast, over a period of 5 weeks, nearly all CSQ
mice showed an increase in LVEDD (Fig. 2A), decrease in % FS
(Fig. 2B), and reduction in wall thickness (Fig. 2C). Thus,
cardiac overexpression of CSQ leads to an initial phenotype of
cardiac hypertrophy with only a mild reduction in systolic
function that progresses to severe cardiac enlargement and
marked LV dysfunction with premature death.
In addition to the time-dependent enlargement in chamber
size, CSQ-overexpressing mice showed a progressive increase
in LV mass as determined by serial echocardiography. Esti-
mated LV mass of CSQ mice at echo #1 was significantly
greater than in wild-type mice (CSQ; 169.1 6 17.9 versus wild-
type; 90.4 6 10.7, mg, p , 0.001). Over the 5-week study period,
little change in estimated LV mass was seen in wild-type ani-
mals, whereas a small increase in the estimated LV mass was
seen in the CSQ-overexpressing mice at echo #2 (CSQ; 185.2 6
9.45 versus wild-type; 90.5 6 7.7, mg, p , 0.001). These data
are consistent with the heart weight data obtained at autopsy
following the hemodynamic study in the 7- and 14-week-old
mice (Table I).
Contractile Dysfunction and Impaired bAR Responsiveness
Associated with CSQ Overexpression—To determine whether
in vivo bAR responsiveness was altered in mice with CSQ
overexpression, cardiac catheterization was performed in 7-
and 14-week old CSQ and age-matched wild-type mice. At 7
weeks of age, basal contractility as measured by the first de-
rivative of LV pressure rise (LV dP/dtmax), was significantly
reduced in the CSQ mice compared with wild-type mice (Fig.
3A, Table I). In response to isoproterenol, 7-week CSQ mice
showed a markedly blunted response as compared with the
brisk increase in LV dP/dtmax observed in wild-type mice (Fig.
3A). Myocardial relaxation (as assessed by LV dP/dtmin) was
also significantly impaired under basal conditions and with
isoproterenol infusion (Fig. 3B). Although LV systolic pressure
was only slightly reduced (Fig. 3C), heart rate was significantly
lower in the CSQ mice at base line and with isoproterenol
stimulation (Fig. 3D). These data show that even in the absence
of overt heart failure, young CSQ mice show marked abnormal-
ities of bAR function in vivo. Cardiac catheterization in 14-
FIG. 2. Progressive deterioration of cardiac function in CSQ
mice as measured by serial echocardiography. Serial echocardio-
graphy was performed in wild type (E, n 5 7) and CSQ (l, n 5 12) mice
at base line (Echo #1) and repeated 5 weeks later (Echo #2). Data for
individual CSQ mice and mean 6 S.E. for both groups are shown. A,
LVEDD; B, % fractional shortening; C, SEPth, septal wall thickness.
Age at first echocardiogram (Echo #1): wild-type (8 weeks), CSQ (8.4 6
0.4 weeks); repeat echocardiogram (Echo #2): wild type (13 weeks), CSQ
(13.3 6 0.4 weeks). *, p , 0.0005, CSQ Echo #2 versus CSQ Echo #1; †,
p , 0.0005, CSQ Echo #2 versus wild-type Echo #2; ‡, p , 0.0005, and
§, p ,0.05, CSQ Echo #1 versus wild-type Echo #1.
TABLE I
Echocardiographic and physiological parameters in 7- and 14-week-old CSQ-overexpressing mice
BW, body weight; HW, heart weight; LVW, left ventricular weight; TL, tibia length; HR, heart rate; LVSP, left ventricular systolic pressure;
LVEDP, left ventricular end diastolic pressure. Data are expressed as mean 6 S.E. Statistical comparison, CSQ vs. wild type for either 7- or
14-week mice or CSQ pace up vs. CSQ for 14 weeks, see p values in footnotes below.
7 weeks 14 weeks
Wild type (n 5 11) CSQ (n 5 13) Wild type (n 5 9) CSQ (n 5 13) CSQ pace up (n 5 4)
LVEDD (mm) 3.3 6 0.8 3.9 6 0.1a 3.7 6 0.1 5.0 6 0.1a
LVESD (mm) 1.7 6 0.7 2.5 6 0.1a 2.0 6 0.1 3.8 6 0.2a
FS (%) 47.5 6 1.9 35.4 6 1.7a 44.8 6 1.8 22.7 6 1.5a
SEPth (mm) 0.65 6 0.03 0.83 6 0.04b 0.74 6 0.03 0.76 6 0.04
mVcfc (circ/s) 2.9 6 0.2 2.3 6 0.2b 2.6 6 0.2 1.53 6 0.1b
BW (g) 18.9 6 1.6 19.6 6 1.0 20.1 6 1.0 20.5 6 0.5
HW/BW (mg/g) 5.3 6 0.1 8.5 6 0.1a 4.8 6 0.1 8.8 6 0.8a
LVW/BW (mg/g) 3.7 6 0.1 6.2 6 0.1a 3.5 6 0.1 6.5 6 0.2a
HW/TL (mg/mm) 6.2 6 0.3 10.4 6 0.3a 5.9 6 0.2 11.1 6 0.5a
LVW/TL (mg/mm) 4.4 6 0.2 7.6 6 0.2a 4.3 6 0.1 7.7 6 0.3a
HR (beats/min) 399 6 14 327 6 13a 401 6 21 307 6 25a 398 6 12c
LV dP/dtmax (mm Hg/s) 8382 6 563 4696 6 299a 8169 6 829 4135 6 442a 2907 6 398c
LV dP/dtmin (mm Hg/s) 26003 6 560 23719 6 284a 26534 6 831 22740 6 346a 22779 6 341
LVSP (mm Hg) 90 6 3 81 6 3 112 6 6 90 6 5a 80 6 4c
LVEDP (mm Hg) 0.9 6 1.0 0.5 6 1.1 10.7 6 1.7 11.0 6 1.5 10.7 6 1.8
a p , 0.0005.
b p , 0.05.
c p , 0.001.
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week old CSQ mice showed a similar pattern with markedly
depressed basal and isoproterenol-stimulated LV dP/dtmax
(Fig. 4A, Table I), significantly impaired LV dP/dtmin (Fig. 4B),
reduced LV systolic pressure (Fig. 4C), and slower heart rate
(Fig. 4D) compared with age-matched controls. These in vivo
data demonstrate that CSQ overexpression is associated with a
severe impairment in bAR responsiveness that occurs early in
the course of the cardiac phenotype and precede the develop-
ment of severe LV enlargement and pump failure.
Since heart rate can affect LV contractility as measured by
the isovolumic phase index, LV dP/dtmax, in vivo hemody-
namic parameters were obtained in a separate group of 14-
week CSQ animals that underwent right atrial pacing to match
heart rate to that of wild-type mice. Increasing heart rate to
'400 beats/min did not increase LV dP/dtmax in the CSQ mice
but rather resulted in a significant decline (Table I).
Overexpression of CSQ Leads to bAR Signaling Defects—To
determine whether overexpression of CSQ leads to abnormal-
ities in bAR signaling, we evaluated receptor-effector coupling
in sarcolemmal membranes from hearts of CSQ mice removed
after the 7- and 14-week hemodynamic study. At both 7 and 14
weeks of age, total bAR density was significantly reduced in
CSQ hearts compared with wild-type hearts (Fig. 5A). In addi-
tion to the decrease in bAR density, the percentage of bARs
exhibiting high-affinity binding for isoproterenol was signifi-
cantly reduced in membranes prepared from both 7- and 14-
week CSQ hearts compared with controls (Fig. 5B). The signif-
icant reduction in the number of high affinity receptors is
consistent with a decreased ability of bARs to form the coupled
hormone-receptor-G protein high affinity state. These changes
occur when receptors are more desensitized (14).
This decrease in bAR density and % high affinity agonist
binding was associated with a marked reduction in isoproter-
enol-stimulated adenylyl cyclase activity in both the 7- and
14-week old mouse hearts, indicating a severe impairment in
bAR coupling (Fig. 5C). These biochemical data are consistent
with the in vivo findings and indicate that cardiac overexpres-
sion of CSQ leads to profound functional uncoupling of bARs
prior to the development of severe pump failure.
Functional bAR uncoupling in human heart failure is asso-
ciated with increased levels and activity of bARK1 (7, 16), a
GRK that phosphorylates and desensitizes bARs. Thus, we
measured GRK activity and bARK1 protein levels in cytosolic
extracts from hearts of CSQ and wild-type mice. We have
previously shown that the cytosolic enzyme bARK1 accounts
for nearly all the GRK activity in cytosolic extracts prepared
from mouse hearts (12). bARK1 protein levels in myocardial
extracts from 7- and 14-week CSQ hearts were determined by
protein immunoblotting following immunoprecipitation of sol-
uble heart extracts with a monoclonal antibody to bARK1. As
shown in Fig. 6, A and B, the level of bARK1 protein was higher
in the hearts of the CSQ mice at both ages compared with
age-matched wild-type mice. Rhodopsin-enriched rod outer seg-
ment membranes were used as a substrate for myocardial GRK
activity. Consistent with the increase in cytosolic bARK1 pro-
tein levels, modest but significant increases in GRK activity
was found in cytosolic extracts obtained from 7-week (1.5 fold,
p , 0.05) and 14-week CSQ mice (1.8-fold, p , 0.05) compared
with age-matched wild-type mice (Fig. 6C). These data demon-
strate that the abnormal receptor-effector coupling found early
in the progressive cardiac phenotype caused by CSQ overex-
pression is associated with increased bARK1 levels, which
likely contributes to the marked functional uncoupling of bARs
when measured both in vivo (responsiveness to isoproterenol
infusion) and in vitro (adenylyl cyclase activity).
Northern blot analysis shows a marked increase in atrial
natriuretic factor mRNA levels in CSQ hearts at both 7 and 14
FIG. 3. In vivo assessment of LV contractile function in re-
sponse to bAR stimulation at 7 weeks. At 7 weeks of age, cardiac
catheterization was performed in closed chest-anesthetized mice using
a 1.4 French high fidelity micromanometer. Four measured parameters
are shown at base line and after progressive infusion of isoproterenol in
wild type (E) n 5 9 and CSQ (l) (n 5 13) mice. A, LV dP/dtmax; B, LV
dP/dtmin; C, LV systolic pressure; D, heart rate. *, p , 0.0001, CSQ
versus wild type. The pattern of change between groups was statisti-
cally significant for LV dP/dtmax, p , 0.00001 (A), LV dP/dtmin, p ,
0.0005 (B).
FIG. 4. In vivo assessment of LV contractile function in re-
sponse to bAR stimulation at 14 weeks. Following the final echo-
cardiogram at 14 weeks of age, cardiac catheterization and was per-
formed as above in wild type (E) n 5 11 and CSQ (l) (n 5 13) mice. A,
LV dP/dtmax; B, LV dP/dtmin; C, LV systolic pressure; D, heart rate.
*p , 0.0001 CSQ versus wild type. The pattern of change between
groups was statistically significant for LV dP/dtmax, p , 0.00001 (A),
LV dP/dtmin, p , 0.005 (B), and heart rate, p , 0.00001 (C).
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weeks compared with age-matched wild-type hearts (Fig. 7).
This is consistent with an induction of a fetal gene program
observed in response to hypertrophic stimuli (11, 15).
DISCUSSION
The present study demonstrates that cardiac-targeted over-
expression of CSQ results in a cardiac phenotype initially char-
acterized by marked LV hypertrophy and mild decrease in
cardiac systolic function, which then rapidly deteriorates to LV
enlargement, severe cardiac dysfunction, and reduction in myo-
cardial wall thickness. This phenotype is associated with a
number of abnormalities in bAR signaling, which occur prior to
the development of overt heart failure as documented by a
decrease in total bAR density and % high affinity agonist
binding, reduced basal and isoproterenol-stimulated adenylyl
cyclase activity, blunted in vivo bAR responsiveness, and the
increase in bARK1 levels.
CSQ is a Ca21 storage protein located in the junctional
sarcoplasmic reticulum lumen, which serves as the source of
the contractile Ca21 released in response to opening of the
ryanodine receptor after activation of the L-type Ca21 channel
in the plasma membrane. Recent electrophysiologic studies in
the CSQ-overexpressing mice has revealed that CSQ is not only
a storage protein but also is involved in the regulation of
intracellular Ca21 homeostasis in heart (10). The data from
this study suggests that chronic suppression of Ca21 release
(caused by overexpression of CSQ) may initiate a cascade of
molecular events that activates the hypertrophic program but
ultimately leads to progressive cardiac decompensation. Inter-
estingly, in this study we show that one of the signaling path-
ways to become affected early in the time course of this pheno-
type is the bAR pathway. In addition to the significant
reduction in bAR density and % high affinity binding in the
hearts of CSQ mice, a marked functional uncoupling of bARs
was shown by the severely depressed response to isoproterenol
in vivo (LV dP/dtmax) and in vitro (adenylyl cyclase activity). A
possible mechanism that contributes to the uncoupling of bARs
in this model is the significant elevation in bARK1 levels. Thus,
our results further point to a possible role for bAR desensiti-
zation in the pathogenesis of the failing heart (8).
FIG. 5. Marked bAR down-regulation and receptor uncoupling
occurs in 7- and 14-week CSQ mice. Membrane preparations from
wild-type (WT, open bar) and CSQ (closed bar) hearts were used to
measure bAR density (A), % high affinity agonist binding (B), and
adenylyl cyclase activity at basal and following isoproterenol ISO stim-
ulation (1024 M) (C). *, p , 0.01 CSQ versus wild-type; †, p , 0.02
isoproterenol (ISO) wild-type versus basal wild type, one factor analysis
of variance. NaF stimulation of adenylyl cyclase activity: 7-week (CSQ
331.7 6 25.2 versus wild type 299.2 6 21.3 pmol/mg protein/min, p 5
ns); 14-week (CSQ 355.6 6 53.6 versus wild type 234.0 6 48.0 pmol/mg
protein/min, p , 0.05), n 5 4–10 for each group.
FIG. 6. bARK1 activity and protein levels were increased in
the hearts of CSQ mice. A and B, immunodetection of bARK1 in
cytosolic extracts from wild-type and CSQ hearts at 7 and 14 weeks of
age is shown. An ;80-kDa protein was visualized by Western blotting
and chemiluminescence following solubilization of cytosolic extracts
and immunoprecipitation. Lane C, 25 mg of purified bARK1. C, bARK1
activity was measured in cytosolic extracts from wild-type and CSQ
hearts by their capacity to phosphorylate the G protein-coupled recep-
tor substrate, rhodopsin. The level of bARK1 activity in CSQ hearts was
calculated as 32P incorporation (fmol/min/mg of cytosolic protein) and
normalized to values obtained in age-matched wild-type hearts; *p ,
0.05, n 5 6–8 for each group. WT, wild type.
FIG. 7. Northern blot analysis in 7- and 14-week CSQ mice.
mRNA levels in the left ventricle from 7- and 14-week-old CSQ-overex-
pressing transgenic mice compared with age-matched wild-type mice.
Filters were hybridized with 32P-labeled cDNA probes, and transcripts
were detected by autoradiography. Each lane represents RNA isolated
from a different mouse ventricle. The following cDNA probes were used:
ANF, atrial natriuretic factor; bMHC, GAPDH, glyceraldehyde-3-phos-
phate dehydrogenase.
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Cardiac hypertrophy is an adaptive response to increased
mechanical stress on the heart characterized by the activation
of a distinct program of gene expression leading to an increase
in myocyte size, expansion of contractile elements, and induc-
tion of an embryonic gene program (17). This early hyper-
trophic adaptation is frequently associated with alterations in
the intracellular Ca21 transient (5). The data from our study
suggest that abnormalities in intracellular Ca21 homeostasis
can primarily activate the hypertrophic program possibly re-
lated to the increase in mechanical stress on the cell as a
consequence of a chronic reduction in force-generating capac-
ity. It is interesting that in many of the CSQ mice studied, the
initial phase was one of increased wall thickness, normal cham-
ber dimensions, and preserved systolic function (Fig. 2). Since
most CSQ mice at 7 weeks did not show LV enlargement, the
marked increase in LV/ body weight is consistent with an early
phenotype of concentric LV hypertrophy that then progresses
to one of dilated cardiomyopathy. The increase in atrial natri-
uretic factor gene expression in 7-week CSQ mice, which per-
sists into the dilated phase at 14 weeks (Fig. 7), is consistent
with the induction of an embryonic gene program and with
data from another model of CSQ overexpression (11).
Recent evidence suggests that signals transduced through G
protein-coupled receptors are critical in the initiation of the
hypertrophic program. These receptor-coupled signals may
participate in the progressive deterioration in cardiac function
that follows with chronic stress (18). In this regard, we have
recently shown an obligatory role for the heterotrimeric gua-
nine nucleotide-binding protein, Gq, in the initiation of ventric-
ular hypertrophy in vivo (19). Whether Gq-coupled receptor
signaling pathways are activated in the hearts of transgenic
mice with CSQ overexpression and progressive cardiomyopa-
thy remains to be tested. Nonetheless it is interesting that CSQ
mice have, as the initial phase, LV hypertrophy, supporting the
concept that alterations in intracellular Ca21 homeostasis are
important in triggering the hypertrophic gene program (20).
Although other mouse models of cardiomyopathy have been
developed (18, 20–24), the CSQ overexpression mouse is
unique for the following reasons. First, the primary abnormal-
ity is in intracellular Ca21 regulation (10), which has previ-
ously been shown to be altered in heart failure (25). Second, the
initial phase is concentric LV hypertrophy and preserved sys-
tolic function, which then leads to LV enlargement and
decompensation.
In summary, this model of cardiac-targeted overexpression of
CSQ should provide a unique opportunity to test hypotheses
related to the transition from cardiac hypertrophy to heart
failure. Using a strategy that combines the mating of gene-
targeted mouse models with comprehensive physiological anal-
ysis of the ensuing cardiac phenotype will allow the direct
testing of the molecular framework involved in the develop-
ment of cardiac hypertrophy and heart failure.
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